drugset / Trial / NCT05013983
Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a phase Ⅰ/Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the safety, tolerability and immunogenicity of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy aged 6-17 years with immunization procedures 0, 21, 42 days and doses (10μg/20μg/40μg).
Timeline
- Start
- 2024-07
- Primary completion
- 2024-12
- Completion
- 2025-12
Outcome
Outcome not reported
Stopped: “Clinical trials not conducted”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant COVID-19 vaccine (Sf9 cells) | Vaccine | 10 ug | — |
| Subject | Recombinant COVID-19 vaccine (Sf9 cells) | Vaccine | 20 ug | — |
| Subject | Recombinant COVID-19 vaccine (Sf9 cells) | Vaccine | 40 ug | — |